Information Provided By:
Fly News Breaks for March 5, 2020
Mar 5, 2020 | 07:00 EDT
Citi analyst Yigal Nochomovitz lowered the firm's price target on Dicerna Pharmaceuticals to $35 from $39 and keeps a Buy rating on the shares. The analyst believes the company's hepatitis B virus is progressing well.
News For DRNA From the Last 2 Days
There are no results for your query DRNA